While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

The early results presented before the San Antonio Breast Cancer Symposium saw an increased rate of progression-free survival ...

The efficacy data could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis.

Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence ...

US pharma giant Pfizer and Alliance Foundation Trials (AFT) have announced results from the Phase III PATINA trial.

Pfizer (PFE) and Alliance Foundation Trials announced results from the Phase 3 PATINA trial demonstrating that the addition ...

Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling ...

Good morning, let’s get straight into the news today. Pfizer said this morning that its drug Ibrance showed efficacy in a ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating ...

Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company ...

Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.